Egetis Therapeutics AB (publ)
STO:EGTX

Watchlist Manager
Egetis Therapeutics AB (publ) Logo
Egetis Therapeutics AB (publ)
STO:EGTX
Watchlist
Price: 6.65 SEK 0.91% Market Closed
Market Cap: 2.4B SEK
Have any thoughts about
Egetis Therapeutics AB (publ)?
Write Note

Egetis Therapeutics AB (publ)
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Egetis Therapeutics AB (publ)
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Egetis Therapeutics AB (publ)
STO:EGTX
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Depreciation & Amortization
kr25.3m
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Depreciation & Amortization
kr10.5m
CAGR 3-Years
35%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Depreciation & Amortization
kr3.7B
CAGR 3-Years
24%
CAGR 5-Years
18%
CAGR 10-Years
28%
BioArctic AB
STO:BIOA B
Depreciation & Amortization
kr7.4m
CAGR 3-Years
N/A
CAGR 5-Years
29%
CAGR 10-Years
N/A
No Stocks Found

Egetis Therapeutics AB (publ)
Glance View

Market Cap
2.4B SEK
Industry
Biotechnology

Egetis Therapeutics AB is a pharmaceutical drug development company, which engages in the development of new drugs for treatment of life threatening diseases. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2011-04-07. The Company’s pipeline include Emcitate developed for the treatment of MCT8 deficiency, PledOx developed to reduce nerve damage associated with chemotherapy and Aladote developed to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning.

EGTX Intrinsic Value
9.63 SEK
Undervaluation 31%
Intrinsic Value
Price

See Also

Back to Top